IRCT20231121060132N1
Recruiting
Phase 3
Investigating the effectiveness of famotidine as a radioprotector in reducing the mucosal and hematological complications of prostate cancer radiotherapy
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kermanshah University of Medical Sciences
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients aged 30 to 75 with prostate cancer candidates for radiotherapy
- •Do not receive PPI drugs and other H2 antagonist drugs
Exclusion Criteria
- •Lack of consent to participate in the study
- •Patients with kidney disease that cannot be prescribed famotidine
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 2
The effectiveness of adding famotidine and vitamin B6 to standard drug treatment in patients with schizophrenia disorderIRCT20150822023705N16Kermanshah University of Medical Sciences80
Completed
Phase 1
Evaluation of the Radioprotective Effect of Famotidine Against Radiotherapy- induced Acute Toxicity in Patients with Prostate CancerProstate CancerBowel toxicityUrinary toxicityCancer - ProstateOral and Gastrointestinal - Normal oral and gastrointestinal development and functionRenal and Urogenital - Normal development and function of male and female renal and urogenital systemACTRN12612000101886School of Paramedical Sciences, Shahid Beheshti Medical University,36
Recruiting
N/A
Bioequivalence study of Famotidine SuspensioIn the present study, the products will be administered to healthy volunteers.IRCT20210519051345N44Tabriz University of Medical Sciences24
Completed
Phase 3
Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patientsIRCT20190707044123N1Rasht University of Medical Sciences64
Recruiting
Phase 3
Famotidine and COVID-19aboratory confirmed COVID-19.COVID-19, virus identifiedU07.1IRCT20200509047364N2Bandare-abbas University of Medical Sciences20